LSE - Delayed Quote GBp

Bioventix PLC (BVXP.L)

2,035.00 +35.00 (+1.75%)

At close: 4:06:50 PM GMT

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Name	Title	Pay	Exercised	Year Born
Mr. Peter John Harrison MA	CEO & Director	362.34k	--	1958
Mr. Bruce Edward Heath Hiscock	CFO & Director	105.84k	--	1958

7 Romans Business Park

East Street

Farnham, GU9 7SX

United Kingdom

44 12 5272 8001 https://www.bioventix.com

Sector:: Healthcare
Industry:
Full Time Employees:: 12

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.

Bioventix PLC’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events Information Not Available

April 9, 2026 at 12:00 AM UTC

Ex-Dividend Date

U.S. markets close in 3h 59m

Bioventix PLC (BVXP.L)

Key Executives

Bioventix PLC

Description

Corporate Governance

Upcoming Events

Recent Events

Related Tickers